AgingResearch.NewsJoin free

CMV PP150 antibodies

There is 1 paper on CMV PP150 antibodies in aging research: 1 observational study in people. The newest story, Nov 11, 2026: “Genetic study links Epstein-Barr antibodies to prostate cancer”.

Biomarker

1 paper studies it1 finding

1 new paper in 30 daysSee all 1 papers on CMV PP150 antibodies

“CMV pp150 showed directionally consistent, meta-analytically significant effects (OR = 1.038, P = 0.020).”
Viral infections and the risk of prostate cancer: a two-sample Mendelian randomization study with multi-cohort replication and an extended viral antibody panelInfectious agents and cancer2026doi:10.1186/s13027-026-00823-x
  • Humans1

Associations

1

Prostate cancer

upin humans1OR 1.038

1 study

  1. CMV PP150 antibodies are associated with prostate cancer in humans (Meta-analytic OR 1.038; P = 0.020).

    “CMV pp150 showed directionally consistent, meta-analytically significant effects (OR = 1.038, P = 0.020).”

    HumansGenetically proxied serological marker; did not survive Bonferroni correction for 37 traits

    Genetic study links Epstein-Barr antibodies to prostate cancer

    Infectious agents and cancer

More on Prostate cancer

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
Infectious Agents and Cancer

Genetic study links Epstein-Barr antibodies to prostate cancer

Across three datasets, genetically predicted antibody levels were linked to higher prostate cancer odds, with a pooled odds ratio of 1.074, versus 1 for no association.Across three datasets, genetically predicted antibody levels were linked to higher prostate cancer odds, with a pooled odds ratio of 1.074, versus 1 for no association.

Mendelian randomizationProstate cancer
Paper

Related